BioCentury | Jan 20, 2021
Management Tracks

Marincola to lead Kite’s cell therapy research; plus moves at T-knife, Applied Molecular Transport, Frequency and NexImmune

Kite Pharma Inc. hired Francesco Marincola as SVP and global head of cell therapy research, effective Feb. 1. Marincola joined the Gilead Sciences Inc. (NASDAQ:GILD) unit from Refuge Biotechnologies Inc., where he was president and CSO. Marincola...
BioCentury | Oct 29, 2020
Finance

Oct. 28 Quick Takes: Mirati raises $800M on KRAS data; BMS-insitro, Novartis-Molecular Partners, Genecast, Gracell, PureTech, Cerevel, Biodesix

Adagrasib readout helps Mirati build war chestResponse rate data in the closely-watched KRAS inhibitor race helped Mirati Therapeutics Inc. (NASDAQ:MRTX) raise $800 million in a follow-on via the sale of 4 million shares at $202...
BioCentury | Oct 8, 2020
Finance

Data Bytes: RADx funding recipients

...job of predicting which patients are infectious than PCR tests. Danielle Golovin NIH Luminostics Inc. Quanterix Corp. Quidel Corp. Sonic Healthcare Illumina Inc. Ceres...
BioCentury | Aug 8, 2020
Finance

Freeline, Checkmate make NASDAQ debuts as 2020 pads its record-setting IPO tally

NASDAQ debuts by Syncona gene therapy company Freeline and Checkmate, a cancer company co-founded by Art Krieg, pushed the year’s IPO haul to $14.7 billion, more than double the amount raised over the same period...
BioCentury | May 2, 2019
Product Development

Evelo breaks from the microbiome pack with non-colonizing bugs

While most companies developing bugs as drugs want their microbes to flourish in hosts, Evelo is designing microbial candidates that exert therapeutic effects without colonizing, replicating or metabolizing -- acting more like biologics than live...
BioCentury | Mar 1, 2019
Product R&D

Mapping microbiome manufacturing

Microbiome companies have been squeezed by the scarcity of contract manufacturers willing to work with tough bacterial strains. While contractors are starting to engage, it could take a big clinical win for them to fully...
BioCentury | Feb 10, 2017
Financial News

Ceres Nanosciences completes venture financing

...On Feb. 2, diagnostic company Ceres Nanosciences Inc. (Manassas, Va.) raised $3 million of a planned...
...to $5.5 million to Ceres over the next year. Ceres Nanosciences Inc. , Manassas, Va. Alicia Parker Ceres...
BioCentury | Mar 17, 2014
Finance

Sangamo swell

Sangamo swell Sangamo BioSciences Inc. (NASDAQ:SGMO) shares have more than doubled over the past few months thanks to a deal with Biogen Idec Inc. (NASDAQ:BIIB) and a steady flow of data. While the gene therapy...
BioCentury | Jan 13, 2014
Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
BioCentury | Sep 2, 2013
Company News

Ceregene, Sangamo deal

Sangamo will acquire gene therapy company Ceregene for 100,000 shares of Sangamo stock, or about $1 million based on Sangamo's close of $10.35 on Aug. 26, before the deal was announced. Ceregene stockholders will also...
Items per page:
1 - 10 of 74
BioCentury | Jan 20, 2021
Management Tracks

Marincola to lead Kite’s cell therapy research; plus moves at T-knife, Applied Molecular Transport, Frequency and NexImmune

Kite Pharma Inc. hired Francesco Marincola as SVP and global head of cell therapy research, effective Feb. 1. Marincola joined the Gilead Sciences Inc. (NASDAQ:GILD) unit from Refuge Biotechnologies Inc., where he was president and CSO. Marincola...
BioCentury | Oct 29, 2020
Finance

Oct. 28 Quick Takes: Mirati raises $800M on KRAS data; BMS-insitro, Novartis-Molecular Partners, Genecast, Gracell, PureTech, Cerevel, Biodesix

Adagrasib readout helps Mirati build war chestResponse rate data in the closely-watched KRAS inhibitor race helped Mirati Therapeutics Inc. (NASDAQ:MRTX) raise $800 million in a follow-on via the sale of 4 million shares at $202...
BioCentury | Oct 8, 2020
Finance

Data Bytes: RADx funding recipients

...job of predicting which patients are infectious than PCR tests. Danielle Golovin NIH Luminostics Inc. Quanterix Corp. Quidel Corp. Sonic Healthcare Illumina Inc. Ceres...
BioCentury | Aug 8, 2020
Finance

Freeline, Checkmate make NASDAQ debuts as 2020 pads its record-setting IPO tally

NASDAQ debuts by Syncona gene therapy company Freeline and Checkmate, a cancer company co-founded by Art Krieg, pushed the year’s IPO haul to $14.7 billion, more than double the amount raised over the same period...
BioCentury | May 2, 2019
Product Development

Evelo breaks from the microbiome pack with non-colonizing bugs

While most companies developing bugs as drugs want their microbes to flourish in hosts, Evelo is designing microbial candidates that exert therapeutic effects without colonizing, replicating or metabolizing -- acting more like biologics than live...
BioCentury | Mar 1, 2019
Product R&D

Mapping microbiome manufacturing

Microbiome companies have been squeezed by the scarcity of contract manufacturers willing to work with tough bacterial strains. While contractors are starting to engage, it could take a big clinical win for them to fully...
BioCentury | Feb 10, 2017
Financial News

Ceres Nanosciences completes venture financing

...On Feb. 2, diagnostic company Ceres Nanosciences Inc. (Manassas, Va.) raised $3 million of a planned...
...to $5.5 million to Ceres over the next year. Ceres Nanosciences Inc. , Manassas, Va. Alicia Parker Ceres...
BioCentury | Mar 17, 2014
Finance

Sangamo swell

Sangamo swell Sangamo BioSciences Inc. (NASDAQ:SGMO) shares have more than doubled over the past few months thanks to a deal with Biogen Idec Inc. (NASDAQ:BIIB) and a steady flow of data. While the gene therapy...
BioCentury | Jan 13, 2014
Finance

Buyside View XXII: 'Grown up' means growth

Stephen Hansen Senior Writer An increase in regulatory approvals and new breakthrough therapies has money managers buying into the concept that biotech has entered a new product cycle that provides a strong fundamental basis for...
BioCentury | Sep 2, 2013
Company News

Ceregene, Sangamo deal

Sangamo will acquire gene therapy company Ceregene for 100,000 shares of Sangamo stock, or about $1 million based on Sangamo's close of $10.35 on Aug. 26, before the deal was announced. Ceregene stockholders will also...
Items per page:
1 - 10 of 74